Endo oxymorphone ER data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Endo's extended-release oxymorphone product shows statistically significant results in a Phase III study of patients with moderate to severe low back pain, the firm reports Oct. 3. In the 12-week, 142-patient study of opioid-experienced patients, oxymorphone ER showed a significant change in average pain intensity compared to placebo (p<0.0001). The results are similar to those from an initial Phase III trial in opioid-naïve patients; Endo announced the results of that initial pivotal trial, conducted under a special protocol assessment, in August. Endo continues to project a complete response to dual "approvable" letters for its ER and immediate-release oxymorphone formulations in 2006...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.